Smith & Nephew’s (SN) Overweight Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their overweight rating on shares of Smith & Nephew (LON:SN) in a research report sent to investors on Tuesday, MarketBeat reports. The firm currently has a GBX 1,180 ($14.41) price target on the stock.

Smith & Nephew Price Performance

Shares of LON:SN opened at GBX 983.80 ($12.01) on Tuesday. The firm’s 50-day simple moving average is GBX 978.94 and its 200-day simple moving average is GBX 1,073.80. The stock has a market cap of £8.58 billion, a P/E ratio of 3,643.70, a PEG ratio of 0.46 and a beta of 0.62. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51.

Insider Activity at Smith & Nephew

In other news, insider John Rogers bought 71,920 shares of Smith & Nephew stock in a transaction on Thursday, December 19th. The shares were purchased at an average price of GBX 972 ($11.87) per share, for a total transaction of £699,062.40 ($853,451.84). Also, insider Rupert Soames bought 5,344 shares of the stock in a transaction dated Monday, November 11th. The stock was purchased at an average price of GBX 936 ($11.43) per share, with a total value of £50,019.84 ($61,066.83). 0.19% of the stock is owned by corporate insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.